

# The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes

Niclas Björn<sup>1</sup>  | Ingrid Jakobsen<sup>1,2</sup>  | Chihiro Udagawa<sup>3</sup>  | Eva Brandén<sup>4,5</sup> | Hirsh Koyi<sup>4,5</sup> | Rolf Lewensohn<sup>6,7</sup> | Luigi De Petris<sup>6,7</sup> | Hitoshi Zembutsu<sup>8</sup>  | Henrik Gréen<sup>1,9</sup> 

<sup>1</sup>Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

<sup>2</sup>Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden

<sup>3</sup>Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan

<sup>4</sup>Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden

<sup>5</sup>Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden

<sup>6</sup>Thoracic Oncology Unit, Tema Cancer, Karolinska University Hospital, Stockholm, Sweden

<sup>7</sup>Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>8</sup>Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan

<sup>9</sup>Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden

## Correspondence

Niclas Björn, Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.  
Email: niclas.bjorn@liu.se

## Funding information

Marcus Borgströms stiftelse; Funds of Radiumhemmet; ALF grants Region Östergötland; Linköping University; Swedish Research Council; Swedish Cancer Society

## Abstract

Gemcitabine/carboplatin-induced myelosuppressive adverse drug reactions (ADRs) are clinical problems leading to patient suffering and dose alterations. There is a need for personalised medicine to improve treatment effects and patients' well-being. We tested four genetic variants, rs11141915, rs1901440, rs12046844 and rs11719165, previously suggested as potential biomarkers for gemcitabine-induced leukopenia/neutropenia in Japanese patients, in 213 Swedish gemcitabine/carboplatin-treated non-small cell lung cancer (NSCLC) patients. DNA was genotyped using TaqMan probes and real-time PCR. The relationships between the risk alleles and low toxicity (non-ADR: Common Terminology Criteria for Adverse Events [CTCAE] grades 0) or high toxicity (ADR: CTCAE grades 3–4) of platelets, leukocytes and neutrophils were evaluated using Fisher's exact test. The risk alleles did not correlate with myelosuppression, and the strongest borderline significance (not withstanding adjustment for multiple testing) was for rs1901440 (neutropenia,  $p = 0.043$ ) and rs11719165 (leukopenia,  $p = 0.049$ ) where the risk alleles trended towards lower toxicity, contrasting with previous study findings. Risk alleles and higher risk scores were more common among our patients. We conclude that the

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Basic & Clinical Pharmacology & Toxicology* published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

genetic variants do not apply to Swedish patients treated with gemcitabine/carboplatin. However, they can still be important in other populations and cohorts, especially in a gemcitabine monotherapy setting, where the causal genetic variation might influence myelosuppressive ADRs.

#### KEYWORDS

adverse drug reactions, carboplatin, gemcitabine, myelosuppression, non-small cell lung cancer

## 1 | INTRODUCTION

It is well known that cancer treatments are harsh and that the worse the prognosis, the harsher these treatments tend to be. The set of available treatment options is rapidly improving and growing, now including surgery, radiation, classical chemotherapy, immune checkpoint inhibitors and targeted drugs. The classical chemotherapies are needed and used as they still have an important role in the treatment of cancer, although decreasingly as the first-line choice. Gemcitabine and carboplatin are two classical chemotherapies that are used in various combinations to combat cancer. Both their individual and combined uses are associated with the induction of severe adverse drug reactions (ADRs),<sup>1–3</sup> which can be dose-limiting and result in reduced, delayed or interrupted treatments. Specifically, myelosuppression in the form of thrombocytopenia, leukopenia and neutropenia is commonly induced by both gemcitabine and carboplatin, and around 50% of treated patients experience Common Terminology Criteria for Adverse Events (CTCAE) grades 3–4 (i.e., severe to life-threatening ADRs).<sup>1–11</sup> There is a need for more personalised treatment regimens to improve both treatment outcomes and patients' well-being.<sup>12,13</sup>

Kiyotani *et al.*<sup>14</sup> performed a genome-wide association study (GWAS) and identified four genetic variants, rs11141915, rs1901440, rs12046844 and rs11719165, that were associated with gemcitabine-induced leukopenia/neutropenia, especially in patients having two to three risk genotypes. Low *et al.*<sup>15</sup> then found further associations between gemcitabine-induced myelosuppressive toxicity for three of the four genetic variants reported by Kiyotani *et al.*<sup>14</sup>: rs1901440 (via linkage disequilibrium [LD] with rs6430443), rs12046844 and rs11719165. However, as pointed out by the authors in Low *et al.*,<sup>15</sup> these two studies are, to some extent, based on the same patient material.

In this study, we aimed to test whether the four proposed genetic variants associated with myelosuppressive ADRs could also be used for risk assessment in our cohort of Swedish gemcitabine/carboplatin-treated non-small cell lung cancer (NSCLC) patients.

## 2 | MATERIALS AND METHODS

### 2.1 | Patients

A total of 215 NSCLC patients had been recruited at the Karolinska University Hospital in Stockholm, Sweden, after giving informed consent as per the Helsinki Declaration. The study was approved by the regional ethics committee in Stockholm, Sweden (DNR-03-413 with amendment 2016/258-32/1). The study was conducted in accordance with the *Basic & Clinical Pharmacology & Toxicology* policy for experimental and clinical studies.<sup>16</sup> This material has been used in other toxicity studies.<sup>8–11</sup> All patients received at least one cycle of carboplatin (AUC = 5, on Day 1) and gemcitabine (1250 mgm<sup>-2</sup>, on Day 1 and Day 8). For this study, 213 of the included patients were included.

### 2.2 | DNA extraction and genotyping

DNA was extracted from blood samples using the QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's protocol. Genotyping of rs11141915, rs1901440, rs12046844 and rs11719165 was carried out according to the manufacturer's protocols using the TaqMan SNP Genotyping Assay (Applied Biosystems, Carlsbad, CA, USA) listed in Table 1, the TaqMan Genotyping Master Mix (Applied Biosystems) and the 7900HT Fast Real-Time PCR System (Applied Biosystems) using standard mode thermal cycling conditions. To confirm the robustness of the genotyping, 20 of the samples were randomly selected and genotyped twice using the same method and one sample determined heterozygous for each genotype was sent to GATC Biotech AG, European Custom Sequencing Centre, Cologne, Germany, for Sanger sequencing for genotype verification.

### 2.3 | Myelosuppression

Platelet, leukocyte and neutrophil counts were registered at baseline and Days 8, 15 and 21 of the first cycle. The

**TABLE 1** Genetic variants genotyped and TaqMan assays used

rsID	Chr	Base pair <sup>a</sup>	Gene	Consequence	Reporter alleles [VIC/FAM] in assay	AssayID
rs11141915	9	90,235,794	DAPK1	Intron	T/G <sup>b</sup>	C__1387009_10
rs1901440	2	134,437,959	-	Intergenic	A/C	C__1356323_10
rs12046844	1	66,238,379	-	Intergenic	C/T <sup>c</sup>	AHLJ2MD
rs11719165	3	194,586,088	-	Intergenic	C/T	C__31058029_20

Note: VIC and FAM are the two fluorescent dyes used to discriminate between the alleles. AssayIDs used by Applied Biosystems.

<sup>a</sup>Base pair in assembly GRCh37.

<sup>b</sup>Converted from A/C as reported by VIC/FAM to facilitate comparison with the previous studies.

<sup>c</sup>Converted from G/A as reported by VIC/FAM to facilitate comparison with the previous studies.

nadir values during the first cycle were graded according to National Cancer Institute (NCI) CTCAE Version 4.03 and used as the toxicity endpoints for platelets, leukocytes and neutrophils, respectively. Also, the maximum toxicity of leukocytes and neutrophils (Max Leu/Neu) was evaluated as a toxicity endpoint.

## 2.4 | HapMap and LD data

Genotype frequencies for the four genetic variants from HapMap-CEU and HapMap-JPT datasets on dbSNP<sup>17</sup> (<https://www.ncbi.nlm.nih.gov/snp/>) were retrieved on 2020-11-15, listed under the ss#: rs11141915, ss43792244; rs1901440, ss78174812; rs12046844, ss87503038; and rs11719165, ss44412686. LD plots of the regions around the genetic variants were generated using Haploview Version 4.2<sup>18</sup> and 1000 genomes phase 3 LD data in the region  $\pm 10,000$  base pairs of the respective genetic variants for both CEU and JPT populations from Ensembl GRCh37.p13 release 102<sup>19</sup> ([http://grch37.ensembl.org/Homo\\_sapiens/Tools/VcftoPed](http://grch37.ensembl.org/Homo_sapiens/Tools/VcftoPed)).

## 2.5 | Statistics

All statistics were calculated using the statistical environment R Version 4.0.3.<sup>20</sup> The 213 patients were split into two groups, ADR (CTCAE grades 3–4) and non-ADR (CTCAE grades 0), based on all toxicity endpoints as in the original study by Kiyotani *et al.*,<sup>14</sup> meaning that patients with intermediate toxicity (CTCAE grades 1–2) were excluded. The allele frequencies of the four genetic variants were then compared between the ADR and non-ADR groups using allelic, dominant and recessive Fisher's exact tests<sup>21</sup> based on the proposed risk alleles. Each patient was then scored according to the number of sites that were homozygous for the risk alleles, that is, using the same risk scoring system as Kiyotani *et al.*<sup>14</sup> This gives a score between 0 and 4 for each patient. The proportion of patients with various risk scores in the

**TABLE 2** Patient characteristics

Age, in years, median (range)	65	(45–83)
Gender, <i>N</i> (%)		
Female	113	53.1%
Male	100	46.9%
Smoking, <i>N</i> (%)		
Current	94	44.1%
Former	98	46.0%
Never	21	9.9%
Histological type, <i>N</i> (%)		
Adenocarcinoma (AC)	131	61.5%
Squamous cell carcinomas (SCC)	40	18.8%
Non-small cell lung cancer (NSCLC)	31	14.6%
Large cell carcinoma (LLC)	10	4.7%
Not specified	1	0.5%
Pathological stage, <i>N</i> (%)		
I	40	18.8%
II	28	13.1%
III	63	29.6%
IV	80	37.6%
Not specified	2	0.9%

ADR and non-ADR groups were compared using Fisher's exact test, to evaluate further if the combination of the genetic variants could be used for predicting the risk of gemcitabine/carboplatin-induced myelosuppression. Bonferroni correction was implemented to test if significant *p*-values surpass adjustments for multiple testing.

## 3 | RESULTS

### 3.1 | Patient characteristics

The clinical characteristics of the 213 NSCLC patients in this study are presented in Table 2, and the overall

myelosuppressive toxicities, graded according to the CTCAE, are shown in Table 3. From this, it is evident that high grades (3–4) are common and experienced by 35%, 23%, 45% and 48% of patients, respectively, for platelets, leukocytes, neutrophils and Max Leu/Neu, during the first treatment cycle.

### 3.2 | Genotyping, HapMap and LD

The genotyping of the four genetic variants using TaqMan probes was successful in all but one sample for which rs12046844 and rs11719165 were undeterminable.

All genotype frequencies are listed in Table 4. The 20 randomly selected samples showed the same results in the replication round, and the selected heterozygous samples were also confirmed as heterozygous using Sanger sequencing (GATC Biotech AG, European Custom Sequencing Centre, Cologne, Germany). Furthermore, the genotypes in this cohort are not out of the Hardy Weinberg equilibrium. The presented genotype frequencies follow distributions similar to the HapMap-CEU cohort (Table 4). However, compared with HapMap-JPT (Table 4), there are some differences in the genotype distributions, especially for rs12046844 and rs11719165 where the risk alleles (C in both cases) are more common

**TABLE 3** Toxicity frequencies in numbers and percentages of platelet, leukocyte and neutrophil nadir values graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

CTCAE grades	0	1	2	3	4	Not specified						
Platelets	44	20.7%	50	23.5%	44	20.7%	44	20.7%	30	14.1%	1	0.5%
Leukocytes	64	30.0%	28	13.1%	72	33.8%	44	20.7%	5	2.3%	0	0.0%
Neutrophils	73	34.3%	4	1.9%	23	10.8%	63	29.6%	33	15.5%	17	8.0%
Max Leu/Neu	59	27.7%	14	6.6%	37	17.4%	68	31.9%	35	16.4%	0	0.0%

Note: Also shown is the maximum toxicity of leukocytes and neutrophils (Max Leu/Neu).

**TABLE 4** Genotype frequencies determined by TaqMan assays and as listed on dbSNP for HapMap-CEU and HapMap-JPT

Genotype	N	%	HapMap-CEU	HapMap-JPT
<b>rs11141915</b>				
T/T	125	58.7%	58.4%	43.0%
T/G	74	34.7%	38.1%	45.3%
G/G	14	6.6%	3.5%	11.6%
Undetermined	0	-	-	-
<b>rs1901440</b>				
A/A	98	46.0%	45.9%	60.0%
A/C	94	44.1%	45.0%	37.6%
C/C	21	9.9%	9.2%	2.4%
Undetermined	0	-	-	-
<b>rs12046844</b>				
C/C	130	61.0%	69.9%	34.9%
C/T	75	35.2%	28.3%	48.8%
T/T	7	3.3%	1.8%	16.3%
Undetermined	1	0.5%	-	-
<b>rs11719165</b>				
C/C	86	40.4%	30.5%	17.8%
C/T	104	48.8%	50.8%	44.4%
T/T	22	10.3%	18.6%	37.8%
Undetermined	1	0.5%	-	-

Note: The genotype of one sample was undeterminable for both rs12046844 and rs11719165.

in the patient cohort presented here and the HapMap-CEU data compared with the HapMap-JPT data. From the LD plots of the regions around the genetic variants ( $\pm 10,000$  base pairs) generated using Haploview and 1000 genomes phase 3 data for CEU and JPT populations, shown in Figure 1, it is evident that the LD structure differs in the underlying populations used in the present study compared with the two previous studies by Kiyotani *et al.*<sup>14</sup> and Low *et al.*<sup>15</sup>


### 3.3 | Genetic variants and toxicity

The results from all association tests between genotypes and myelosuppressive toxicities are listed in Table 5. Overall, the associations were mainly non-significant, and for many of the toxicity endpoints, the risk allele frequencies were similar in the ADR and non-ADR groups and for some even higher in the non-ADR groups. Two

of the tests yielded borderline significant results, rs1901440 for neutrophils ( $p = 0.043$ , odds ratio [OR] = 0.52, 95% confidence interval [CI] = 0.26–1.01) and rs11719165 for leukocytes ( $p = 0.049$ , OR = 0.42, 95% CI = 0.17–1.01). However, these are not significant after corrections for multiple testing.

### 3.4 | Toxicity risk scores

All 213 patients were then scored according to their number of homozygous genetic variants. The number of patients for each toxicity risk score was 23 (11%), 64 (30%), 83 (39%), 40 (19%) and 3 (1%), respectively, for scores 0, 1, 2, 3 and 4. It is worth pointing out that, overall, patients with high scores (2–4) were more common in our patient cohort as they accounted for 59% of the patients compared with about 35% in the previous study.<sup>14</sup> We also found that three patients were homozygous for all four proposed



**FIGURE 1** Linkage disequilibrium plots generated in Haploview using the regions 10,000 base pairs upstream and downstream of the four genetic variants (whose position is indicated by the yellow dots), rs1901440, rs11141915, rs11719165 and rs12046844, in the 1000 genomes phase 3 data for the respective populations, CEU and JPT, extracted using Ensembl GRCh37.p13 release 102

TABLE 5 Results from Fisher's exact test analysing the risk alleles for platelets, leukocytes, neutrophils and Max Leu/Neu (the maximum toxicity of leukocytes and neutrophils)

Risk allele	p-value										95% CI		
	ADR (CTCAE 3–4)		RAF		Non-ADR (CTCAE 0)		RAF	Allelic	Dominant	Recessive	OR	Lower	Upper
T	G/G	G/T	T/T	T/T	G/G	G/T	T/T	T/T					
rs11141915													
Platelets	4	21	49	0.80	2	18	24	0.332	1.000	<b>0.242</b>	1.63	0.71	3.75
Leukocytes	1	14	34	0.84	3	23	38	<b>0.313</b>	0.632	0.326	0.67	0.32	1.37
Neutrophils	7	33	56	0.76	6	23	44	1.000	1.000	<b>0.875</b>	0.92	0.47	1.79
Max Leu/Neu	7	34	62	0.77	3	20	36	0.891	<b>0.748</b>	1.000	0.74	0.12	3.39
rs1901440													
Platelets	A/A	A/C	C/C	C/C	A/A	A/C	C/C	0.663	<b>0.255</b>	0.531	0.62	0.27	1.41
Leukocytes	39	26	9	0.30	18	23	3	<b>0.330</b>	0.331	0.580	0.73	0.41	1.31
Neutrophils	22	22	5	0.33	22	33	9	0.099	<b>0.043</b>	0.799	0.52	0.26	1.01
Max Leu/Neu	51	36	9	0.28	27	38	8	0.085	<b>0.049</b>	0.588	0.51	0.24	1.02
rs12046844													
Platelets	T/T	T/C	C/C	C/C	T/T	T/C	C/C	0.865	1.000	1.000	0.91	0.43	1.88
Leukocytes	3	23	48	0.80	1	14	29	0.858	1.000	<b>0.840</b>	0.91	0.38	2.20
Neutrophils	1	15	32	0.82	1	19	44	0.221	1.000	<b>0.148</b>	0.61	0.30	1.20
Max Leu/Neu	4	36	56	0.77	3	19	51	0.84	0.653	0.309	0.70	0.36	1.30
rs11719165													
Platelets	T/T	T/C	C/C	C/C	T/T	T/C	C/C	0.676	0.770	<b>0.437</b>	0.69	0.30	1.58
Leukocytes	8	39	27	0.63	6	18	20	0.121	1.000	<b>0.049</b>	0.42	0.17	1.01
Neutrophils	4	31	13	0.59	5	29	30	0.253	0.629	<b>0.208</b>	0.67	0.34	1.30
Max Leu/Neu	12	50	34	0.61	7	33	33	<b>0.336</b>	0.602	0.402	1.28	0.77	2.12

Note: OR and CI are displayed for the test (allelic, dominant or recessive) with the lowest associated p-value, marked in bold, for each toxicity. Abbreviations: ADR, adverse drug reaction; CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events; OR, odds ratio; RAF, risk allele frequency.

risk alleles, whereas no such patient was found in the Japanese cohort. Of the three top risk scoring patients, one had a high toxicity profile with CTCAE grades 4 for both platelets and neutrophils (and therefore also for Max Leu/Neu), whereas the other two patients had low toxicity profiles with CTCAE grades 0–1 for all toxicity endpoints.

Based on the risk scores, we then tested if there were any differences in the proportion of risk scores between the patients in the ADR and non-ADR groups using Fisher's exact test, for which the results are listed in Table 6. This showed that there were no significant differences for any of the toxicities on any level as we tested risk scores 2 versus 0–1, 2–4 versus 0–1, 3–4 versus 0–1 and 3–4 versus 0–2.

## 4 | DISCUSSION

In the present study, we investigated whether four genetic variants, rs11141915, rs1901440, rs12046844 and rs11719165, previously found to be associated with the risk of myelosuppression (specifically leukopenia/neutropenia) in gemcitabine-treated patients<sup>14,15</sup> could be used for risk assessment in our cohort of 213 gemcitabine/carboplatin-treated NSCLC patients. The genotyping showed that the frequencies of the genetic variants in our patients follow the distribution of the alleles in the HapMap CEU population on dbSNP.

The association tests did not show any robust significant associations between the proposed risk alleles and

**TABLE 6** Risk scores in ADR and non-ADR groups for platelets, leukocytes, neutrophils and Max Leu/Neu

Risk score	Platelets		p-value (comparing risk scores)
	ADR (CTCAE 3–4)	Non-ADR (CTCAE 0)	
0	7	3	
1	19	14	1.00 (2 vs. 0–1)
2	31	20	0.84 (2–4 vs. 0–1)
3	16	6	0.44 (3–4 vs. 0–1)
4	1	1	0.48 (3–4 vs. 0–2)
Risk score	Leukocytes		p-value (comparing risk scores)
	ADR (CTCAE 3–4)	Non-ADR (CTCAE 0)	
0	5	3	
1	15	20	0.83 (2 vs. 0–1)
2	18	24	0.70 (2–4 vs. 0–1)
3	11	15	0.63 (3–4 vs. 0–1)
4	0	2	0.67 (3–4 vs. 0–2)
Risk score	Neutrophils		p-value (comparing risk scores)
	ADR (CTCAE 3–4)	Non-ADR (CTCAE 0)	
0	12	3	
1	32	22	0.17 (2 vs. 0–1)
2	34	32	0.16 (2–4 vs. 0–1)
3	17	14	0.39 (3–4 vs. 0–1)
4	1	2	0.70 (3–4 vs. 0–2)
Risk score	Max Leu/Neu		p-value (comparing risk scores)
	ADR (CTCAE 3–4)	Non-ADR (CTCAE 0)	
0	12	3	
1	34	19	0.58 (2 vs. 0–1)
2	36	22	0.41 (2–4 vs. 0–1)
3	20	13	0.39 (3–4 vs. 0–1)
4	1	2	0.56 (3–4 vs. 0–2)

Note: p-values from Fisher's exact test comparing the proportions of risk scores.

Abbreviations: ADR, adverse drug reaction; CTCAE, Common Terminology Criteria for Adverse Events.

any type of myelosuppressive toxicity in our patients when split into the ADR and non-ADR groups. Two tests were borderline significant, rs1901440 for neutrophils ( $p = 0.043$ ) and rs11719165 for leukocytes ( $p = 0.049$ ), although in these cases, the proposed risk alleles trended towards slightly lower levels of toxicity. However, no major conclusions should be drawn based on this as the tests did not withstand adjustments for multiple testing, meaning that the trend of risk alleles towards lower toxicity in our cohort should be interpreted with caution. Similarly, we did not see any significant associations between higher risk scores (combinations of multiple homozygous risk alleles) and myelosuppression. Our study findings suggest that the four genetic variants cannot be applied for the prediction of myelosuppressive ADRs in CEU patients treated with gemcitabine/carboplatin combination chemotherapy. However, the reason for this is probably multifactorial as there are some important differences to highlight between our study and previous studies.<sup>14,15</sup> These considerable differences are related to the treatments, toxicity and study populations. Firstly, the risk alleles and their combinations were overall more common in Swedes than in Japanese patients. Also, the severity of the myelosuppression and the proportion of patients experiencing CTCAE grades 3–4 were higher in our study, which could mask the effects of the genetic variants previously shown, as in the present study 23.0%–48.4% experienced CTCAE grades 3–4, 12.7%–46.9% experienced CTCAE grades 1–2 and 20.7%–34.3% experienced CTCAE grade 0, whereas only 11.3% and 19.2% of patients experienced leukopenia/neutropenia CTCAE grades 3–4, 70.1% and 26.6% experienced CTCAE grades 1–2 and 18.7% and 54.2% experienced CTCAE grade 0 in previous studies,<sup>14,15</sup> respectively. The main difference is that our patients received gemcitabine/carboplatin combination chemotherapy whereas the original study indicated the risk alleles specifically for leukopenia/neutropenia in patients receiving gemcitabine monotherapy. Therefore, the current study might have lost some specificity regarding the risk alleles due to the study set-up. However, as gemcitabine is used in many combinations, it is important to know whether the risk alleles still work as markers of toxicity risk even in combination regimes as well as gemcitabine monotherapy. Unfortunately, the present study indicates that the four investigated genetic markers might not be able to predict myelosuppressive toxicity following gemcitabine/carboplatin combination chemotherapy. Furthermore, as the frequency of the genetic variants and the LD landscape around them differs between the Swedish and Japanese populations, the relationship between the risk alleles and myelosuppression may be lost. Therefore, our results do not mean that the proposed genetic variants

are not useful; rather, there is still evidence<sup>14,15</sup> to suggest that the genetic variants can be useful and should be investigated further, mainly in patients treated with gemcitabine monotherapy, although the genetic variant could still be important in combination treatments for other populations, including Japanese patients. Lastly, it may be that the causal genetic variation associated with toxicity is not in LD with the four genetic variants in our Swedish study population.

In conclusion, our results do not indicate any association between the previously identified risk alleles with myelosuppressive ADRs in patients treated with gemcitabine/carboplatin combination chemotherapy. However, the results are important for further understanding of chemotherapy-induced myelosuppression and for pharmacogenetics and the personalised medicine research community working on solving this clinical issue.

## ACKNOWLEDGEMENTS

This research was funded by the Swedish Cancer Society (H.G.), the Swedish Research Council (H.G.), Linköping University (H.G.), ALF grants Region Östergötland (H.G.), the Funds of Radiumhemmet (R.L. and L.D.P.) and Marcus Borgströms stiftelse (H.G.). The funders had no role in study design, data collection, data analysis, preparation of the manuscript or decision to publish.

## CONFLICT OF INTERESTS

The authors have no conflicts of interest to declare.

## ORCID

Niclas Björn  <https://orcid.org/0000-0001-6806-4527>  
 Ingrid Jakobsen  <https://orcid.org/0000-0003-4450-0333>  
 Chihiro Udagawa  <https://orcid.org/0000-0002-3430-2555>  
 Hitoshi Zembutsu  <https://orcid.org/0000-0002-1674-1968>  
 Henrik Gréen  <https://orcid.org/0000-0002-8015-5728>

## REFERENCES

1. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. *Cancer Chemother Pharmacol.* 1982;9(3):140-147. doi: 10.1007/BF00257742
2. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. *Cancer Nurs.* 1999;22(2):176-183. doi: 10.1097/00002820-199904000-00011
3. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. *J Clin Oncol.* 2005;23(33):8380-8388. doi: 10.1200/JCO.2005.01.2781



4. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. *J Clin Oncol*. 2005;23(1):142-153. doi:10.1200/JCO.2005.03.037
5. Zatloukal P, Petruželka L, Zemanová M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer: a phase III randomized trial. *Lung Cancer*. 2003;41(3):321-331. doi:10.1016/S0169-5002(03)00233-2
6. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27(19):3217-3224. doi:10.1200/JCO.2008.20.9114
7. Imamura F, Nishio M, Noro R, et al. Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study). *Chemotherapy*. 2011;57(4):357-362. doi:10.1159/000330481
8. Green H, Hasmats J, Kupersmidt I, et al. Using whole-exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities. *Clin Cancer Res*. 2016;22(2):366-373. doi:10.1158/1078-0432.CCR-15-0964
9. Bjorn N, Sigurgeirsson B, Svedberg A, et al. Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. *Pharmacogenomics J*. 2020;20(2):179-191. doi:10.1038/s41397-019-0099-8
10. Svedberg A, Bjorn N, Sigurgeirsson B, et al. Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. *Lung Cancer*. 2020;147:106-114. doi:10.1016/j.lungcan.2020.07.005
11. Bjorn N, Badam TV, Spalinskas R, et al. Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. *NPJ Syst Biol Appl*. 2020;6(1):25 doi:10.1038/s41540-020-00146-6
12. Udagawa C, Zembutsu H. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy. *Cancer Sci*. 2020;111(10):3445-3457. doi:10.1111/cas.14609
13. Church D, Kerr R, Domingo E, et al. 'Toxgnostics': an unmet need in cancer medicine. *Nat Rev Cancer*. 2014;14(6):440-445. doi:10.1038/nrc3729
14. Kiyotani K, Uno S, Mushiroda T, et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. *Pharmacogenet Genomics*. 2012;22(4):229-235. doi:10.1097/FPC.0b013e32834e9eba
15. Low SK, Chung S, Takahashi A, et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. *Cancer Sci*. 2013;104(8):1074-1082. doi:10.1111/cas.12186
16. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. *Basic Clin Pharmacol Toxicol*. 2021;128(1):4-8. doi:10.1111/bcpt.13492
17. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res*. 2001;29(1):308-311. doi:10.1093/nar/29.1.308
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005;21(2):263-265. doi:10.1093/bioinformatics/bth457
19. Yates AD, Achuthan P, Akanni W, et al. Ensembl 2020. *Nucleic Acids Res*. 2020;48(D1):D682-D688. doi:10.1093/nar/gkz966
20. RCoreTeam. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2021.
21. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. *Nat Protoc*. 2011;6(2):121-133. doi:10.1038/nprot.2010.182

**How to cite this article:** Björn N, Jakobsen I, Udagawa C, et al. The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes. *Basic Clin Pharmacol Toxicol*. 2022;130(4):513-521. doi:10.1111/bcpt.13712